WEILL CORNELL SCIENTISTS REVEAL HOW THE PROTEIN WORKS AND HOW THE DRUG GUMS IT UP, OFFERING NEW HOPE FOR TREATMENT OF AGGRESSIVE CANCER
Researchers have discovered how an experimental drug is capable of completely eradicating human lymphoma in mice after just five doses. The study, led by researchers at Weill Cornell Medical College, sets the stage for testing the drug in clinical trials of diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, itself the seventh most frequently diagnosed cancer in the U.S.
In the journal Cell Reports, published today online, the scientists describe how the powerful master regulatory transcription factor Bcl6 regulates the genome, ensuring that aggressive lymphomas survive and thrive. They also show how the Bcl6 inhibitor, developed at Weill Cornell, effectively gums up the protein, stopping it from working.
While Bcl6 is active in a number of cancers, including leukemia and breast cancer, work testing a Bcl6 inhibitor is most advanced in DLBCL. “That’s because we desperately need a new strategy to treat this lymphoma — many patients are resistant to currently available treatments,” says the study’s senior investigator, Dr. Ari Melnick, Gebroe Family Professor of Hematology/Oncology and director of the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences at Weill Cornell.
Dr. Melnick developed the first BCL6 inhibitors nine years ago, and has continued to improve upon the design of these drugs so they could be used to treat cancer patients. He has since collaborated with colleagues at many institutions in a systemic effort to understand how both Bcl6 and its inhibitor drugs function.
In a study published in March in Nature Immunology, Dr. Melnick and his team reported that it is possible to shut down Bcl6 in DLBCL without affecting its vital role in the T cells and macrophages needed to support a healthy immune system. The protein has long been considered too complex to target with a drug as it also is crucial to proper function of many immune system cells, not just B cells gone bad.
That finding suggested Bcl6 inhibiting drugs may have few side effects, says Dr. Melnick, who is also a hematologist-oncologist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
The latest study was designed to understand exactly how Bcl6 promotes DLBCL.
Transcription factors are responsible for either inhibiting or promoting the expression of genes, and master regulatory transcription factors are like transcription factors on steroids: their actions regulate thousands of genes in different kinds of cells. Bcl6 can control the type of immune cell that develops in the bone marrow — pushing them to become B cells, T cells, or macrophages — and it has a primary role in the developmental phase of B cells, during which they generate specific antibodies against pathogens.
The researchers found that in order to help B cells produce antibodies against an infection, Bcl6 “builds a huge shopping mall-style complex” that sits on top of a stretch of the genome. By binding onto these genes, Bcl6 deactivates the DNA, stopping genes from producing RNA and proteins. “Bcl6 acts like a barcode reader. When it sees that barcode — the DNA sequence — it attaches there,” Dr. Melnick.
Normally, the protein complex goes away after an immune reaction has been successfully mounted against the pathogen. But when it doesn’t, and remains stuck to the genes, DLBCL can result. That’s because Bcl6 is inhibiting genes that stop cells from dividing and that sense damage to the genome, Dr. Melnick says. “We now know the genes that Bcl6 is repressing and how that helps lymphoma develop and survive.”
Bcl6 also has a second, independent function that Dr. Melnick says acts like a switch on railroad track that routes a train in one direction or another. One track is needed when antibodies are required for an immune response, while the other keeps B cells in a constant state of division.
The researchers found that in order for DLBCL to survive, Bcl6 needs to maintain both its shopping mall protein complex and keep the train tracks on the path toward B cell division.
To their surprise, they also found that both the complex and the train switch attach to the Bcl6 protein at the same site. “They fit into the same keyholes on Bcl6,” Dr. Melnick says. “There are two identical binding sites on the protein surface.”
Even better, the Bcl6 inhibitor they developed was designed to fit into that same keyhole.
“This is wonderfully serendipitous — our drug just happens to be able to overcome both of the biological mechanisms that are key to survival of aggressive lymphoma,” Dr. Melnick says, adding that the inhibitor completely eradicated DLBCL in mice in a short time, with no detectable side effects.
The Latest on: Lymphoma
- Mother-of-three, 29, with stage three Hodgkin's Lymphoma claims government told her she did not have 'enough cancer' to receive two types of benefitson August 18, 2019 at 10:56 pm
A mother-of-three with stage three Hodgkin's Lymphoma says the government told her she did not have enough cancer to receive two types of benefits. Katie Larn, 29, went for a check up after feeling ...
- Chesterbrook Academy Donates to The Leukemia & Lymphoma Societyon August 16, 2019 at 12:00 pm
Summer campers from Chesterbrook Academy Preschool in Centreville recently donated nearly $250 to the Leukemia & Lymphoma Society, which funds lifesaving blood cancer research around the world and ...
- Lift STRONG benefit raises more than $3,300 for Leukemia & Lymphoma Society and Navy SEAL Foundationon August 16, 2019 at 7:09 am
The Underground Strength Gym’s 13th annual Lift STRONG Fundraiser to benefit the Leukemia & Lymphoma Society and the Navy SEAL Foundation, conducted last weekend at its Manasquan location, raised more ...
- Medicines targeting multiple sclerosis and lymphoma are among new specialty drugs available through AllianceRx Walgreens Primeon August 15, 2019 at 7:47 am
Leading specialty and home delivery pharmacy expands offering of hard-to-find medicines to meet needs of patients with rare conditions ORLANDO, Fla., Aug. 12, 2019 /PRNewswire/ -- AllianceRx ...
- Celebrating the Leukemia & Lymphoma Society's 2019 Man & Woman of the year's record breaking fundraisingon August 14, 2019 at 3:02 pm
John Huber and Lynn Liu were named the 2019 Leukemia & Lymphoma Society's Man & Woman of the year. Huber raised a record-setting $163,000 in memory of his late wife. Liu raised $83,000. Money raised ...
- CAR T-cell therapy shows activity in lymphoma despite lack of measurable diseaseon August 14, 2019 at 10:54 am
Tisagenlecleucel showed measurable in vivo expansion in patients with relapsed or refractory diffuse large B-cell lymphoma who had no measurable disease after bridging therapy, according to a recent ...
- OS rate for Hodgkin lymphoma remains high with PET response-adapted therapyon August 13, 2019 at 9:42 am
Patients with advanced, persistent Hodgkin lymphoma who switched to an escalated treatment regimen as part of a PET-adapted therapy approach achieved favorable PFS but a high rate of secondary ...
- UAMS Myeloma Center receives $542,486 grant from Leukemia & Lymphoma Societyon August 11, 2019 at 11:19 pm
Brian Walker, Ph.D., with the Myeloma Center at the University of Arkansas for Medical Sciences (UAMS) has received a $542,486, three-year grant from the Leukemia & Lymphoma Society to look at changes ...
- A New Model for Lymphoma Drug Discoveryon August 11, 2019 at 1:45 pm
Mantle cell lymphoma is an aggressive subtype of non-Hodgkin's lymphoma that claims the lives of tens of thousands of people every year. Mantle cell lymphoma is considered incurable, even though new ...
- Medicare to cover CAR-T therapy for leukemia, lymphomaon August 9, 2019 at 7:22 am
A breakthrough gene therapy will be covered for certain types of lymphoma and leukemia, Medicare says. Chimeric antigen receptor T-cell (CAR-T) therapy boosts a patient's own immune cells to fight ...
via Google News and Bing News